MLB releases 2015 report on drug program

The independent administrator for Major League Baseball's Joint Drug Prevention and Treatment Program issued his annual report for 2015 on Tuesday.

The report showed that of 8,158 urine and blood tests administered from Dec. 2, 2014, until Monday, 10 adverse analytical findings were reported by the testing laboratory that resulted in discipline.

Seven were for performance-enhancing substances, two were for stimulants and one was for DHEA (dehydroepiandrosterone), a hormone that is produced by the human body.

Of the seven positives for PEDs, four were for the anabolic steroid Stanozolol, one was for Stanozolol and Boldenone, one was for Ipamorelin and one was for testosterone. Of the positives for stimulants, one was for Adderall and one for Phentermine. The other positive was for DHEA.

The 1,622 blood specimens collected were specifically to reveal the use of human growth hormone (HGH). No positive findings were reported.

There were 113 therapeutic-use exemptions granted for those who tested positive because of stimulants: 111 for ADD (attention deficit disorder), one for Gynecomastia -- swollen male breast tissue caused by a hormone imbalance -- and one for an olecranon stress fracture of the elbow.

The report, which covers players on the 40-man rosters of the 30 clubs only, also stated that in the past five years beginning in 2011, 30,482 tests have been administered, 1,381 of them in the offseason.

The report was signed by Dr. Jeffrey M. Anderson, the independent drug administrator.

Barry M. Bloom is a national reporter for MLB.com and writes an MLBlog, Boomskie on Baseball. Follow @boomskie on Twitter. This story was not subject to the approval of Major League Baseball or its clubs.